Ovarian Cancer Clinical Trials in Baltimore

Showing 121-140 of 274 trials

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

NCT02915523

The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation. Additionally, this study will evaluate the effectiveness of entinostat in combination with avelumab at the determined dose in terms of progression free survival compared to avelumab plus placebo in participants with refractory or recurrent epithelial ovarian cancer.

Epithelial Ovarian CancerPeritoneal CancerFallopian Tube Cancer

Syndax Pharmaceuticals140 participantsStarted Dec 2016

Tampa, Florida, United States • West Palm Beach, Florida, United States • Chicago, Illinois, United States +9 more locations

COMPLETEDPhase 1< 1 mile

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

NCT03219268

The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with margetuximab in HER2+ advanced solid tumors. Pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and the anti-tumor activity of tebotelimab will also be assessed.

Advanced Solid TumorsHematologic NeoplasmsOvarian Cancer+7 more

MacroGenics277 participantsStarted Aug 2017

Gilbert, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +37 more locations

Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

Ovarian Cancer Trials in Other Cities

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer

A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

Non-Viral TCR Gene Therapy

Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

A Study Of TeleGenetics Versus Usual Care To Increase Access To Cancer Genetic Services

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

ATR Inhibitor Elimusertib (BAY1895344) Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)

Other Conditions in Baltimore